The Committee on Safety of Medicines (CSM) received 116 spontaneous reports of 197 adverse reactions between September 1995 and March 1996. Ten of these reactions involved the oesophagus: oesophageal reflux (4), oesophagitis (4), and oesophageal ulceration (2). Adverse gastrointestinal reactions are more common when this drug is used in conjunction with aspirin and NSAIDs.
The CSM recommend that the risk of oesophageal reactions should be minimised by:
Alendronate sodium should not be given to patients with:
Cautious use of alendronate sodium is required for patients with upper gastrointestinal problems.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.